Potential of Unengineered and Engineered Wharton’s Jelly Mesenchymal Stem Cells as Cancer Inhibitor Agent
Cancer is one the most common life-threatening diseases. Cancer cases worldwide are forecast to rise by 75% in the future. Although cancer therapies have been improved, many tumors remain unresponsive to conventional treatments, such as radiation and chemotherapy. Therefore, novel strategies in treating and managing the disease are urgently needed. Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) have recently been shown to possess anti-cancer activities as well as tumor-homing ability. These cells are able to migrate to sites of neoplastic growth in vivo and their secretory products display tumoricidal activity both in vitro and in vivo models of human cancer. Recent reports also suggest that the anti-cancer potential of WJ-MSCs can also be enhanced through genetic engineering. This review will summarize the current understanding on the interactions between WJ-MSCs and tumor cells, as well as the potential use of both un-engineered and engineered WJ-MSCs as an anti-cancer agent..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Immunology, endocrine & metabolic agents in medicinal chemistry - 15(2015), 2, Seite 128-137 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Widowati, Wahyu [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1986721043 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC1986721043 | ||
| 003 | DE-627 | ||
| 005 | 20230518124703.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170131s2015 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a fidpha_zeitschriften_20170130.pp |
| 035 | |a (DE-627)OLC1986721043 | ||
| 035 | |a (DE-599)GBVOLC1986721043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Widowati, Wahyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential of Unengineered and Engineered Wharton’s Jelly Mesenchymal Stem Cells as Cancer Inhibitor Agent |
| 264 | 1 | |c 2015 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Cancer is one the most common life-threatening diseases. Cancer cases worldwide are forecast to rise by 75% in the future. Although cancer therapies have been improved, many tumors remain unresponsive to conventional treatments, such as radiation and chemotherapy. Therefore, novel strategies in treating and managing the disease are urgently needed. Wharton's Jelly-derived mesenchymal stem cells (WJ-MSCs) have recently been shown to possess anti-cancer activities as well as tumor-homing ability. These cells are able to migrate to sites of neoplastic growth in vivo and their secretory products display tumoricidal activity both in vitro and in vivo models of human cancer. Recent reports also suggest that the anti-cancer potential of WJ-MSCs can also be enhanced through genetic engineering. This review will summarize the current understanding on the interactions between WJ-MSCs and tumor cells, as well as the potential use of both un-engineered and engineered WJ-MSCs as an anti-cancer agent. | ||
| 700 | 1 | |a Krisanti Jasaputra, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Sumitro, Sutiman B. |e verfasserin |4 aut | |
| 700 | 1 | |a Widodo, M. Aris |e verfasserin |4 aut | |
| 700 | 1 | |a Yaprianto, Kelvin |e verfasserin |4 aut | |
| 700 | 1 | |a Bachtiar, Indra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunology, endocrine & metabolic agents in medicinal chemistry |d San Francisco, Calif. : Bentham Science Publ., 2006 |g 15(2015), 2, Seite 128-137 |w (DE-627)507526643 |w (DE-600)2221719-8 |w (DE-576)435514261 |x 1871-5222 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2015 |g number:2 |g pages:128-137 |
| 856 | 4 | 0 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1871-5222&volume=15&issue=2&spage=128 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2015 |e 2 |h 128-137 | ||